文献速递中药与中成药合理使用中医内科

丹参片与利伐沙班在大鼠和人肝微粒体中的相互作用评价

Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes.
PubMed 文献 · Front Pharmacol · 2022-07-19

本研究在大鼠和人肝微粒体中评价丹参片对利伐沙班代谢的抑制作用,并检测丹参片及八种活性成分对CYP酶的抑制效果。结果显示丹参片强效抑制利伐沙班代谢,其脂溶性成分二氢丹参酮I强效抑制大鼠CYP3A和CYP2J。结论提示丹参片与利伐沙班联用存在潜在相互作用,临床需加强利伐沙班药物监测并调整剂量。

要点

  • 丹参片可抑制利伐沙班在大鼠和人肝微粒体中的代谢。
  • 二氢丹参酮I强效抑制大鼠CYP3A和CYP2J活性。
  • 两药联用需加强利伐沙班监测并调整剂量。

核心结论

  • 丹参片与利伐沙班之间存在潜在相互作用,丹参片抑制利伐沙班代谢,可能与二氢丹参酮I等脂溶性成分强效抑制CYP酶(尤其CYP3A和CYP2J)有关。
  • 临床同时使用丹参片和利伐沙班时,有必要加强利伐沙班的药物监测并调整剂量。

研究设计与样本

  • 研究在大鼠和人肝微粒体中评价丹参片对利伐沙班代谢的抑制作用。
  • 研究评估丹参片及其八种活性成分(二氢丹参酮I、丹参酮I、丹参酮IIA、隐丹参酮、丹参素、丹酚酸A、丹酚酸B、丹酚酸C)对细胞色素P450(CYP)酶的抑制效果。

主要发现

  • 丹参片强效抑制利伐沙班在大鼠和人肝微粒体中的代谢。
  • 二氢丹参酮I强效抑制大鼠CYP3A和CYP2J活性,IC50分别为13.85和6.39 μM。
  • 丹参片在利伐沙班代谢中为混合性抑制剂,在大鼠和人肝微粒体中的Ki值分别为0.72和0.25 mg/ml。

关键数值与推荐

  • 二氢丹参酮I抑制大鼠CYP3A的IC50为13.85 μM。
  • 二氢丹参酮I抑制大鼠CYP2J的IC50为6.39 μM。
  • 丹参片抑制利伐沙班代谢的大鼠肝微粒体Ki为0.72 mg/ml。
  • 丹参片抑制利伐沙班代谢的人肝微粒体Ki为0.25 mg/ml。

临床怎么用

  • 临床联用丹参片与利伐沙班时,应加强利伐沙班的药物监测。
  • 根据监测结果考虑调整利伐沙班剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The combination of Salvia miltiorrhiza (Danshen) and rivaroxaban is a promising treatment option in clinical practice in China, but the herb-drug interaction between Danshen and rivaroxaban remains unclear. Therefore, this study aims to reveal the interaction between Danshen and rivaroxaban. We not only investigated the inhibitory properties of Danshen tablet on rivaroxaban metabolism in rat and human liver microsomes but also evaluated the inhibitory effects of Danshen tablet and its eight active components (dihydrotanshinone I, tanshinone I, tanshinone IIA, cryptotanshinone, danshensu, salvianolic acid A, salvianolic acid B, and salvianolic acid C) on cytochrome P450 (CYP) enzymes. The results showed that Danshen tablet potently inhibited the metabolism of rivaroxaban in rat and human liver microsomes. In the CYP inhibition study, we found that dihydrotanshinone I, the active component of Danshen tablet, potently inhibited the activities of rat CYP3A and CYP2J, with IC50 values at 13.85 and 6.39 μM, respectively. In further inhibition kinetic study, we found that Danshen tablet is a mixed inhibitor in rivaroxaban metabolism in rat and human liver microsomes, with the K i value at 0.72 and 0.25 mg/ml, respectively. In conclusion, there is a potential interaction between Danshen tablet and rivaroxaban. Danshen tablet inhibits the metabolism of rivaroxaban, which may be because its lipid-soluble components such as dihydrotanshinone I strongly inhibit the activities of CYP enzymes, especially CYP3A and CYP2J. Therefore, when Danshen tablet and rivaroxaban are used simultaneously in the clinic, it is necessary to strengthen the drug monitoring of rivaroxaban and adjust the dosage.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang X, Fa J, Zhang Y, et al. Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes. Front Pharmacol. 2022. PMID: 35928264. doi:10.3389/fphar.2022.950525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。